30 apr 2019
CPhI North America 2019
Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Exhibitor at CPhI North America 2019 stand 121

About us

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 17,000 employees globally, is the largest manufacturer of antineoplastic drugs, surgical drugs and contrast media in China. Its operating income was over USD 2.4 billion in 2018. All APIs and finish dosage forms have passed national GMP authentication. APIs are approved by US-FDA, EDQM, PMDA and TGA. FDFs are approved by US-FDA, EU and PMDA.

Specs about this supplier

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: APIs |Finished Dosage Forms |Injectables More

Products featured at CPhI North America 2019

Categories affiliated with Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Event information

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA Visit us at stand 121

Click map to see full floor plan.